Clinical trials: Malignant Brain Neoplasm
Glioblastoma Multiforme, Glioma
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
In this study, investigators will conduct a phase I/II trial in recurrent (temozolomide resistant) glioma patients. The overall goal of this study is to provide a foundation for future studies with indoximod tested in newly…
- Conditions
- Glioblastoma Multiforme, Glioma, Gliosarcoma, Malignant Brain Tumor
- Trial name
- NCT02052648
- Testing
- Indoximod, Temozolomide, Bevacizumab
- Where
- 17 sites in United States
- Volunteers
- 160 people
- Sponsor
- NewLink Genetics Corporation
Glioblastoma Multiforme of Brain, Anaplastic Astrocytoma of Brain
Trial of C134 in Patients With Recurrent GBM
The purpose of this project is to obtain safety information in small groups of individuals, scheduled to receive escalating doses of C134, a cancer killing virus (HSV-1) that has been genetically engineered to safely replicate…
- Conditions
- Glioblastoma Multiforme of Brain, Anaplastic Astrocytoma of Brain, Gliosarcoma of Brain
- Trial name
- C134-HSV-1 (NCT03657576)
- Testing
- C134
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Alabama at Birmingham
Glial Cell Tumors, Malignant Gliomas
Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
Currently, there are few effective treatments for the following aggressive brain tumors: glioblastoma multiforme, anaplastic astrocytoma, gliomatosis cerebri, gliosarcoma, or brainstem glioma.
- Conditions
- Glial Cell Tumors, Malignant Gliomas, Glioblastoma Multiforme, Anaplastic Astrocytoma
- Trial name
- NCT00879437
- Testing
- Valproic acid, Bevacizumab, Radiation therapy
- Where
- 6 sites in United States
- Volunteers
- 38 people
- Sponsor
- Baylor College of Medicine
HLA-A2 Positive Cells Present, Metastatic Malignant Neoplasm
Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes
This pilot clinical trial studies the side effects of anti-ESO (cancer/test antigen) murine T-cell receptor (mTCR)-transduced autologous peripheral blood lymphocytes and combination chemotherapy with cyclophosphamide and…
- Conditions
- HLA-A2 Positive Cells Present, Metastatic Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain
- Trial name
- NCT02774291
- Testing
- Aldesleukin, Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes, Cyclophosphamide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Albert Einstein College of Medicine
Malignant Neoplasm Brain
Pre-operative Stereotactic Radiosurgery Followed by Resection for Brain Metastases
The primary goal of this research study is to determine the efficacy of giving pre-operative radiosurgery to patients pending resection of a brain metastasis.
- Trial name
- NCT02514915
- Testing
- Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Christopher Wilke
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating children who have advanced…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00024258
- Testing
- arsenic trioxide
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Malignant Glioma of Brain
Panitumumab and Irinotecan for Malignant Gliomas
This is a phase II study of the combination of panitumumab with irinotecan in malignant glioma patients. The primary objective of the study is to determine the activity of the combination of panitumumab with irinotecan as…
- Trial name
- NCT01017653
- Testing
- Irinotecan, Panitumumab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Annick Desjardins
Glioblastoma, Recurrent Adult Brain Neoplasm
Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma
The purpose of this research study is to test the safety, tolerability, and effectiveness of the combination of three drugs, sorafenib (Nexavar®), valproic acid (Depakote®), and sildenafil (Viagra®), when used to treat high-grade…
- Conditions
- Glioblastoma, Recurrent Adult Brain Neoplasm, Malignant Glioma, WHO Grade III Glioma
- Trial name
- NCT01817751
- Testing
- sorafenib tosylate, valproic acid, sildenafil citrate
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Virginia Commonwealth University
Extensive Stage Lung Small Cell Carcinoma, Malignant Solid Neoplasm
Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread
This phase I trial seeks to find out the best dose, possible benefits and/or side effects of entinostat in combination with atezolizumab, carboplatin and etoposide for the treatment of previously untreated aggressive lung cancer…
- Conditions
- Extensive Stage Lung Small Cell Carcinoma, Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Brain
- Trial name
- NCT04631029
- Testing
- Atezolizumab, Carboplatin, Entinostat
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Breast Neoplasm, Brain Neoplasm
Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)
The purpose of this study is to determine whether temozolomide can be used as a prophylaxis against brain recurrence in participants with metastatic breast cancer.
- Conditions
- Breast Neoplasm, Brain Neoplasm, Second Neoplasm
- Trial name
- STOP (NCT00638963)
- Testing
- temozolomide
- Volunteers
- 6 people
- Sponsor
- Merck Sharp & Dohme LLC
Recurrent High-Grade Gliomas, Malignant Gliomas
Bevacizumab for Recurrent Malignant Glioma
Background: Bevacizumab is a genetically engineered antibody that blocks the growth of new blood vessels in tumors. Inhibiting the formation of these blood vessels may slow or stop disease progression by diminishing the supply of…
- Trial name
- NCT00271609
- Testing
- Bevacizumab
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma
PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer
This phase II trial studies how well intensity modulated radiation therapy adjusted by positron emission tomography (PET) scanning together with combination chemotherapy works in treating patients with stage II-IV non-small cell…
- Conditions
- Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma
- Trial name
- PAINT (NCT02073968)
- Testing
- Carboplatin, Computed Tomography, Intensity-Modulated Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Albert Einstein College of Medicine
Glioblastoma, Gliosarcoma
Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme
Primary objective: To determine the 6-month progression free survival of patients with recurrent glioblastoma multiforme (GBM) treated with Erlotinib plus Sirolimus.
- Trial name
- NCT00672243
- Testing
- Erlotinib + sirolimus
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Duke University
Malignant Glioma, Glioblastoma
Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab
This is a Phase 1/2 clinical trial to evaluate a new combination of drugs, marizomib (MRZ) and bevacizumab (BEV; Avastin®), for the treatment of WHO Grade IV malignant glioma.
- Trial name
- NCT02330562
- Testing
- MRZ, BEV
- Where
- 5 sites in United States, Canada
- Volunteers
- 121 people
- Sponsor
- Celgene
Primary Brain Tumors, Metastatic Malignant Neoplasm to Brain
Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome (DM-CHOC-PEN) in Patients With Brain Tumors
DM-CHOC-PEN is a polychlorinated pyridine cholesteryl carbonate that has demonstrated antineoplastic activities in patients with advanced cancers - melanoma, lung, breast and glioblastoma multiforme (GBM) involving the CNS during…
- Trial name
- DM-CHOC-PEN (NCT02038218)
- Testing
- 4-Demethyl-4-cholestryloxycarbonylpenclomedine
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- DEKK-TEC, Inc.
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
This phase III trial compares the effect of adding whole brain radiotherapy with hippocampal avoidance and memantine versus stereotactic radiosurgery alone in treating patients with cancer that has spread to the brain and come…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Breast Neoplasm
- Trial name
- NCT04588246
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 81 sites in United States, Canada and 1 more
- Volunteers
- 19 people
- Sponsor
- NRG Oncology
Glioblastoma, Gliosarcoma
Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)
Primary objective: To evaluate activity of imatinib mesylate and hydroxyurea among patients with progressive/recurrent grade II low-grade glioma (LGG) as measured by 12-month progression free survival Secondary objectives: To…
- Trial name
- NCT00615927
- Testing
- Imatinib Mesylate & Hydroxyurea
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Duke University
HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma
Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer
This randomized phase II trial studies how well whole-brain radiation therapy or stereotactic radiosurgery with or without lapatinib ditosylate works in treating patients with breast cancer that has too many of a protein called…
- Conditions
- HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma
- Trial name
- NCT01622868
- Testing
- Laboratory Biomarker Analysis, Lapatinib Ditosylate, Stereotactic Radiosurgery
- Where
- 302 sites in United States, Canada and 1 more
- Volunteers
- 143 people
- Sponsor
- National Cancer Institute (NCI)
Brain Neoplasms, Adult, Malignant
Stereotactic Radiosurgery (SRS) Dose-Escalation Study for Brain Metastasis
SRS dose escalation for brain metastases in radiation-naïve patients will establish true tolerable doses, which may exceed the current standard doses.
- Trial name
- SRS (NCT02645487)
- Testing
- Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- University of Texas Southwestern Medical Center
Brain Neoplasms, Primary Malignant
Topotecan by Intracerebral Clysis for Recurrent Primary Malignant Brain Tumors
This study will evaluate the safety and efficacy of a chemotherapeutic drug (topotecan) as it is given directly into brain tumors by a delivery technique called convection-enhanced delivery.
- Trial name
- NCT00308165
- Testing
- Convection-Enhanced Delivery, Topotecan
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Columbia University